MedTrace Logo

A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects

NCT00830427 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2019-01-31

No results posted yet for this study

Summary

This study (A7881006) is the first multiple dose study in moderate asthmatic subjects and aims to determine the safety and efficacy of PF-00610355 when subjects take PF-00610355 on a daily basis for 4 weeks in subjects maintained on inhaled corticosteroid.

Conditions

  • Asthma, Bronchial
  • Lung Diseases, Obstructive
  • Respiratory Tract Diseases
  • Bronchial Diseases

Interventions

DRUG

PF-00610355

100 mcg, QD, dry powder inhaler

DRUG

PF - 00610355

600 mcg, QD, dry powder inhaler

OTHER

Placebo

QD, dry powder inhaler

DRUG

PF - 00610355

300 mcg, QD, dry powder inhaler

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-15
Primary Completion
2009-12-31
Completion
2009-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00830427 on ClinicalTrials.gov